Please note that UPSpace will be unavailable from Friday, 2 May at 18:00 (South African Time) until Sunday, 4 May at 20:00 due to scheduled system upgrades. We apologise for any inconvenience this may cause and appreciate your understanding.
dc.contributor.author | Hiesgen, J.![]() |
|
dc.contributor.author | Schutte, Clara-Maria![]() |
|
dc.date.accessioned | 2024-01-29T09:01:23Z | |
dc.date.available | 2024-01-29T09:01:23Z | |
dc.date.issued | 2023-04 | |
dc.description.abstract | Autoimmune encephalitis (AE) represents a growing number of severe autoimmune-inflammatory diseases affecting both the white and grey matter of the brain. In part 1 of this series, we focused on the epidemiology, pathophysiology and clinical presentation of this condition, with two illustrative cases. In this part, we introduce the clinical criteria for AE, particularly for the diagnosis of anti-N-methyl-D-aspartate (NMDA) receptor encephalitis, which were developed to facilitate immune treatment in suspected cases before antibody results are available. We subsequently discuss the work-up, differential diagnosis and treatment options for patients with this disease. | en_US |
dc.description.department | Neurology | en_US |
dc.description.librarian | am2024 | en_US |
dc.description.sdg | SDG-03:Good heatlh and well-being | en_US |
dc.description.uri | https://samajournals.co.za/index.php/samj/index | en_US |
dc.identifier.citation | Hiesgen, J. & Schutte, C.M. 2023, 'Autoimmune encephalitis : epidemiology, pathophysiology and clinical spectrum (part 2)', South African Medical Journal, vol. 113, no. 4, pp. 1136-1139. https://DOI.org/10.7196/SAMJ.2023.v113i4.875. | en_US |
dc.identifier.issn | 0256-9574 (print) | |
dc.identifier.issn | 2078-5135 (online) | |
dc.identifier.other | 10.7196/SAMJ.2023.v113i4.875 | |
dc.identifier.uri | http://hdl.handle.net/2263/94133 | |
dc.language.iso | en | en_US |
dc.publisher | South African Medical Association | en_US |
dc.rights | © 2023 Juliane Hiesgen, Prof Schutte. This work is licensed under a Creative Commons Attribution-NonCommercial 4.0 International License. | en_US |
dc.subject | Autoimmune-inflammatory diseases | en_US |
dc.subject | Brain | en_US |
dc.subject | Diagnosis | en_US |
dc.subject | Encephalitis | en_US |
dc.subject | Autoimmune encephalitis (AE) | en_US |
dc.subject | N-methyl-d-aspartate (NMDA) | en_US |
dc.subject | SDG-03: Good health and well-being | en_US |
dc.subject.other | Health sciences articles SDG-03 | |
dc.subject.other | SDG-03: Good health and well-being | |
dc.title | Autoimmune encephalitis : epidemiology, pathophysiology and clinical spectrum (Part 2) | en_US |
dc.type | Article | en_US |